Rheumatoid Arthritis
Conditions
Interventions
17. Dose/regimen:
Per subgroup patients will be randomized in three treatment strategies of DMARD
combination therapy. Treatment strategies are aimed to achieve *no arthritis*
in all subgroups. Pat
RA group)
a. Methotrexate in combination with a cumulative high dose corticosteroids
b. Combination of MTX, SSZ, HCQ and single bridging i.m. corticosteroids
c. Combination of MTX, SSZ, HCQ and a cum
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: To be able te sign informed consent -Patients must meet the inclusion criteria for the REACH. That is: object arthritis, pain and or limitation of motion in 2 or more joints in combination with 2 of the following criteria: morningstiffness, tangential pain in MTP/MCP, pos fam anamneses, symm presentation, unexplained fatigue.
Exclusion criteria
Exclusion criteria: Complaints> 1 year by trauma or overload, no possibility to communicate, definitive diagn of gout, infectious arthritis or systematic disease, use of antirheumatic preparates before start study, contra indication for medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| •Primary endpoints: Disease activity: Disease activity: Area under the curve (AUC) DAS Functionality: AUC HAQ during 1 year of therapy Joint damage: Radiologic progression | — |
Secondary
| Measure | Time frame |
|---|---|
| •Secondary endpoints: Absence of arthritis WHO/ILAR Core-set Self-assessed disease activity (RADAI) Cost (medical direct/indirect) Mediation reduction in time | — |
Countries
Netherlands
Outcome results
None listed